Evidence map›Paper›PMID 19172341›Full record

Trial reportOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2009

Milk ribonuclease-enriched lactoferrin induces positive effects on bone turnover markers in postmenopausal women.

S Bharadwaj, A G T Naidu, G V Betageri, N V Prasadarao, A S Naidu

Abstract readRandomized Controlled Trial
PubMed Publisher
In one paragraph

Trial report in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 95 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Inflammatory responses improve with milk ribonuclease-enriched lactoferrin supplementation in postmenopausal women.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2010
    Trial
  6. Review
  7. Review
  8. Review
  9. Review
  10. Frontiers in medicine · 2023
    Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Anti-Osteoporotic Effects of Kukoamine B Isolated fromInternational journal of molecular sciences · 2019
    Article
  20. Ursolic Acid Prevents Retinoic Acid-Induced Bone Loss in Rats.Chinese journal of integrative medicine · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

S BharadwajN-terminus Research Laboratory, 981 Corporate Center Dr., # 110, Pomona, CA 91768, USA.
A G T Naidu
G V Betageri
N V Prasadarao
A S Naidu
Pomona College · USChildren's Hospital of Los Angeles · USWestern University of Health Sciences · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledCurrent treatments for postmenopausal osteoporosis suffer from side effects. Safe and natural milk proteins, ribonuclease, and lactoferrin promote formation of new capillaries and bone formation. A ribonuclease-enriched lactoferrin supplement studied here, demonstrates significant reduction in resorption and increase in formation, towards restoring the balance of bone turnover within 6 months.

introductionOsteoporosis, a major health issue among postmenopausal women, causes increased bone resorption and reduced bone formation. A reduction in angiogenesis could also contribute to this imbalance. Current treatments such as hormone replacement therapy and bisphosphonates have drawbacks of severe side effects. Milk ribonuclease (RNase) is known to promote angiogenesis and lactoferrin (LF) to stimulate bone formation by osteoblasts. We examine the effect of ribonuclease-enriched lactoferrin supplement on the bone health of postmenopausal women.

methodsA total of 38 healthy, postmenopausal women, aged 45 to 60 years were randomized into placebo or RNAse-enriched-LF (R-ELF) supplement groups. The bone health status was monitored by assessing bone resorption markers, serum N-telopeptides (NTx), and urine deoxypyridinoline (Dpd) crosslinks and serum bone formation markers, bone-specific alkaline phosphatase (BAP), and osteocalcin (OC).

resultsR-ELF supplementation demonstrated a decrease in urine Dpd levels by 14% (19% increase for placebo) and serum NTx maintained at 24% of the baseline (41% for placebo), while serum BAP and OC levels showed a 45% and 16% elevation (25% and 5% for placebo).

conclusionsR-ELF supplementation demonstrated a statistically significant reduction in bone resorption and increase in osteoblastic bone formation, to restore the balance of bone turnover within a short period.

Indexed as

MilkAlkaline PhosphataseAmino AcidsAnimalsBiomarkersBone RemodelingBone ResorptionCalcium, DietaryCollagen Type IDietary SupplementsFemaleHumansLactoferrinMiddle AgedOsteocalcinOsteoporosis, PostmenopausalAlkaline PhosphataseAmino AcidsBiomarkersCalcium, DietaryCollagen Type Icollagen type I trimeric cross-linked peptidedeoxypyridinolineLactoferrinOsteocalcinPeptidesRibonucleases

Identifiers

PMID19172341
OpenAlexW2059840692

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.